Compagnie Lombard Odier SCmA’s Lexicon Pharmaceuticals LXRX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Sell	480,000 -30,000	-6%	-$58.4K	0.01%	169
2026 Q1	$796K	Buy	510,000 +100,000	+24%	+$145K	0.01%	171
2025 Q4	$472K	Hold	410,000	–	–	0.01%	203
2025 Q3	$554K	Buy	410,000 +80,000	+24%	+$90.8K	0.01%	187
2025 Q2	$312K	Buy	330,000 +220,000	+200%	+$143K	﹤0.01%	207
2025 Q1	$50.7K	Hold	110,000	–	–	﹤0.01%	354
2024 Q4	$81.2K	Buy	110,000 +10,000	+10%	+$12.1K	﹤0.01%	307
2024 Q3	$157K	Buy	100,000 +6,000	+6%	+$10.7K	﹤0.01%	262
2024 Q2	$158K	Hold	94,000	–	–	﹤0.01%	261
2024 Q1	$226K	Hold	94,000	–	–	﹤0.01%	249
2023 Q4	$144K	Hold	94,000	–	–	﹤0.01%	323
2023 Q3	$102K	Hold	94,000	–	–	﹤0.01%	352
2023 Q2	$215K	Hold	94,000	–	–	0.01%	254
2023 Q1	$228K	Sell	94,000 -4,000	-4%	-$9.17K	0.01%	267
2022 Q4	$187K	Hold	98,000	–	–	0.01%	303
2022 Q3	$235K	Hold	98,000	–	–	0.01%	279
2022 Q2	$182K	Buy	98,000 +94,000	+2,350%	+$179K	﹤0.01%	303
2022 Q1	$8K	Hold	4,000	–	–	﹤0.01%	558
2021 Q4	$16K	Hold	4,000	–	–	﹤0.01%	600
2021 Q3	$19K	Hold	4,000	–	–	﹤0.01%	567
2021 Q2	$18K	Hold	4,000	–	–	﹤0.01%	561
2021 Q1	$23K	Hold	4,000	–	–	﹤0.01%	564
2020 Q4	$14K	Hold	4,000	–	–	﹤0.01%	523
2020 Q3	$6K	Hold	4,000	–	–	﹤0.01%	490
2020 Q2	$8K	Hold	4,000	–	–	﹤0.01%	485
2020 Q1	$8K	Hold	4,000	–	–	﹤0.01%	446
2019 Q4	$17K	Sell	4,000 -1,500	-27%	-$5.77K	﹤0.01%	425
2019 Q3	$17K	Hold	5,500	–	–	﹤0.01%	429
2019 Q2	$34K	Hold	5,500	–	–	﹤0.01%	389
2019 Q1	$30K	Hold	5,500	–	–	﹤0.01%	438
2018 Q4	$37K	Hold	5,500	–	–	﹤0.01%	406
2018 Q3	$59K	Hold	5,500	–	–	﹤0.01%	407
2018 Q2	$66K	Hold	5,500	–	–	﹤0.01%	403
2018 Q1	$47K	Buy	5,500 +1,500	+38%	+$13.9K	﹤0.01%	461
2017 Q4	$40K	Buy	4,000 +2,200	+122%	+$22.9K	﹤0.01%	498
2017 Q3	$22K	Hold	1,800	–	–	﹤0.01%	599
2017 Q2	$30K	Sell	1,800 -700	-28%	-$10.8K	﹤0.01%	578
2017 Q1	$36K	Buy	2,500 +1,800	+257%	+$26.7K	﹤0.01%	576
2016 Q4	$10K	Hold	700	–	–	﹤0.01%	749
2016 Q3	$13K	Hold	700	–	–	﹤0.01%	823
2016 Q2	$10K	Sell	700 -3,871	-85%	-$52.5K	﹤0.01%	830
2016 Q1	$55K	Sell	4,571 -3,000	-40%	-$31.5K	﹤0.01%	701
2015 Q4	$101K	Buy	+7,571	New	+$93.1K	﹤0.01%	594
2015 Q2	–	Sell	-7,571	Closed	-$50K	–	893
2015 Q1	$50K	Hold	7,571	–	–	﹤0.01%	785
2014 Q4	$48K	Buy	+7,571	New	+$61K	﹤0.01%	635

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Compagnie Lombard Odier SCmA's LXRX Position: Q2 2026 in Review

Compagnie Lombard Odier SCmA reduced its Lexicon Pharmaceuticals (LXRX) stake by 5.9% in Q2 2026, selling an estimated $58.4K and leaving 480,000 shares worth $1.15M. The position accounts for 0.01% of the portfolio, ranked #169.

Compagnie Lombard Odier SCmA first reported a position in LXRX in Q4 2014 and has held it in 45 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

Compagnie Lombard Odier SCmA held 480,000 shares of Lexicon Pharmaceuticals worth $1.15M as of Q2 2026.
Compagnie Lombard Odier SCmA sold 30,000 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $58.4K.
Lexicon Pharmaceuticals made up 0.01% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #169 holding.
Compagnie Lombard Odier SCmA first reported a position in Lexicon Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.